Monthly
US$200
Billed every month
Acetylcysteine Granules(乙酰半胱氨酸颗粒)
Companies, stages and changes, with each record available on this page.
No changes recorded by this site in the last 90 days
Complete CDE snapshot: 2026/11/10 07:27
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders19View records ↓
Under-review filings4View records ↓
This year’s generic filers2View records ↓
NHSA approval numbers29View records ↓
API companies with A status12View records ↓
Chemical-drug catalogue
Loaded records: 19 holders; 1 in the quality-and-efficacy consistency-evaluation category, and 17 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 海南海神同洲制药有限公司 | 海南海神同洲制药有限公司 | 国药准字H20265343 | 2026/07/21 | 0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南海神同洲制药有限公司 | 海南海神同洲制药有限公司 | 国药准字H20265344 | 2026/07/21 | 0.2g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南欧拉医药科技有限公司 | 湖南新汇制药股份有限公司 | 国药准字H20264992 | 2026/06/30 | 0.2g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南广升誉制药有限公司 | 江苏诚康药业有限公司 | 国药准字H20263738 | 2026/03/31 | 0.2g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南广升誉制药有限公司 | 江苏诚康药业有限公司 | 国药准字H20263739 | 2026/03/31 | 0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 郑州韩都药业集团有限公司 | 郑州韩都药业集团有限公司 | 国药准字H20255768 | 2025/10/21 | 0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 郑州韩都药业集团有限公司 | 郑州韩都药业集团有限公司 | 国药准字H20255767 | 2025/10/21 | 0.2g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湘北威尔曼制药股份有限公司 | 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 2025/05/20 | 0.1g | Not stated by source | CDE |
| 湘北威尔曼制药股份有限公司 | 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 2025/05/20 | 0.2g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 南京易亨制药有限公司 | 南京易亨制药有限公司 | 国药准字H20249427 | 2024/11/22 | 0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广东百澳药业有限公司 | 广东百澳药业有限公司 | 国药准字H20030732 | 2024/11/08 | 0.2g | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 哈尔滨华瑞生化药业有限责任公司 | 海南海神同洲制药有限公司 | 国药准字H20249277 | 2024/11/05 | 0.2g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江寰领医药科技有限公司 | 浙江亚峰药厂有限公司 | 国药准字H20244740 | 2024/08/27 | 0.2g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江金华康恩贝生物制药有限公司 | 浙江金华康恩贝生物制药有限公司 | 国药准字H20247184 | 2024/08/05 | 0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广东百澳药业有限公司 | 广东百澳药业有限公司 | 国药准字H20247160 | 2024/07/11 | 0.1g | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 四川海梦智森生物制药有限公司 | 浙江赛默制药有限公司 | 国药准字H20243785 | 2024/05/21 | 0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 河北龙海药业有限公司 | 河北龙海药业有限公司 | 国药准字H20243804 | 2024/05/21 | 0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川海梦智森生物制药有限公司 | 浙江赛默制药有限公司 | 国药准字H20243786 | 2024/05/21 | 0.2g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江恒研医药科技有限公司 | 浙江赛默制药有限公司 | 国药准字H20243085 | 2024/01/23 | 0.2g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江恒研医药科技有限公司 | 浙江赛默制药有限公司 | 国药准字H20243084 | 2024/01/23 | 0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 杭州云柏医药科技有限公司 | 浙江赛默制药有限公司 | 国药准字H20234434 | 2023/10/27 | 0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 杭州云柏医药科技有限公司 | 浙江赛默制药有限公司 | 国药准字H20234433 | 2023/10/27 | 0.2g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南赛立克药业有限公司 | 海南赛立克药业有限公司 | 国药准字H20234324 | 2023/10/18 | 0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江众延医药科技有限公司 | 石家庄市华新药业有限责任公司 | 国药准字H20234160 | 2023/09/12 | 0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南赛立克药业有限公司 | 海南赛立克药业有限公司 | 国药准字H20233011 | 2023/01/03 | 0.2g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 桂林华信制药有限公司 | 桂林华信制药有限公司 | 国药准字H20223842 | 2022/11/15 | 0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江金华康恩贝生物制药有限公司 | 浙江金华康恩贝生物制药有限公司 | 国药准字H20223846 | 2022/11/15 | 0.2g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南九典制药股份有限公司 | 湖南九典制药股份有限公司 | 国药准字H20223727 | 2022/10/11 | 0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| — | 海南赞邦制药有限公司 | 国药准字H20000471 | 2000/08/04 | 3g:0.2g(以乙酰半胱氨酸计) | Other drug (其他药品) | CDE |
| — | 海南赞邦制药有限公司 | 国药准字H20000472 | 2000/08/04 | 3g:0.1g(以乙酰半胱氨酸计) | Other drug (其他药品) | CDE |
| 浙江众延医药科技有限公司 | 石家庄市华新药业有限责任公司 | 国药准字H20269242 | 2026/09/29 | 0.2g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 29 distinct approval numbers and 18 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 南京易亨制药有限公司 | 国药准字H20249427 | 0.1g | Category B (乙) | XR05CBY116N001010101605 | NHSA |
| 浙江众延医药科技有限公司 | 国药准字H20234160 | 0.1g | Category B (乙) | XR05CBY116N001010102753 | NHSA |
| 河北万龙药业有限公司 | 国药准字H20243804 | 0.1g | Category B (乙) | XR05CBY116N001010102766 | NHSA |
| 郑州韩都药业集团有限公司 | 国药准字H20255768 | 0.1g | Category B (乙) | XR05CBY116N001010103251 | NHSA |
| 哈尔滨华瑞生化药业有限责任公司 | 国药准字H20249277 | 0.2g | Category B (乙) | XR05CBY116N001010103634 | NHSA |
| 浙江金华康恩贝生物制药有限公司 | 国药准字H20223846 | 0.2g | Category B (乙) | XR05CBY116N001010104656 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20223727 | 0.1g | Category B (乙) | XR05CBY116N001010104942 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 0.1g | Category B (乙) | XR05CBY116N001010105025 | NHSA |
| 桂林华信制药有限公司 | 国药准字H20223842 | 0.1g | Category B (乙) | XR05CBY116N001010105199 | NHSA |
| 海南海神同洲制药有限公司 | 国药准字H20265343 | 0.1g | Category B (乙) | XR05CBY116N001010105777 | NHSA |
| 海南赛立克药业有限公司 | 国药准字H20233011 | 0.2g | Category B (乙) | XR05CBY116N001010105805 | NHSA |
| 海南赞邦制药有限公司 | 国药准字H20000472 | 0.1g | Category B (乙) | XR05CBY116N001010105838 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20263738 | 0.2g | Category B (乙) | XR05CBY116N001010181251 | NHSA |
| 四川海梦智森生物制药有限公司 | 国药准字H20243785 | 0.1g | Category B (乙) | XR05CBY116N001010183150 | NHSA |
| 杭州云柏医药科技有限公司 | 国药准字H20234433 | 0.2克 | Category B (乙) | XR05CBY116N001010183549 | NHSA |
| 古戈尔药业(海南)有限责任公司 | 国药准字H20243084 | 0.1克 | Category B (乙) | XR05CBY116N001010184227 | NHSA |
| 浙江寰领医药科技有限公司 | 国药准字H20244740 | 0.2g | Category B (乙) | XR05CBY116N001010184239 | NHSA |
| 南京易亨制药有限公司 | 国药准字H20249427 | 0.1g | Category B (乙) | XR05CBY116N001010201605 | NHSA |
| 浙江众延医药科技有限公司 | 国药准字H20234160 | 0.1g | Category B (乙) | XR05CBY116N001010202753 | NHSA |
| 河北万龙药业有限公司 | 国药准字H20243804 | 0.1g | Category B (乙) | XR05CBY116N001010202766 | NHSA |
| 郑州韩都药业集团有限公司 | 国药准字H20255768 | 0.1g | Category B (乙) | XR05CBY116N001010203251 | NHSA |
| 浙江金华康恩贝生物制药有限公司 | 国药准字H20223846 | 0.2g | Category B (乙) | XR05CBY116N001010204656 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20223727 | 0.1g | Category B (乙) | XR05CBY116N001010204942 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 0.1g | Category B (乙) | XR05CBY116N001010205025 | NHSA |
| 桂林华信制药有限公司 | 国药准字H20223842 | 0.1g | Category B (乙) | XR05CBY116N001010205199 | NHSA |
| 海南赛立克药业有限公司 | 国药准字H20233011 | 0.2g | Category B (乙) | XR05CBY116N001010205805 | NHSA |
| 海南赞邦制药有限公司 | 国药准字H20000472 | 0.1g | Category B (乙) | XR05CBY116N001010205838 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20263738 | 0.2g | Category B (乙) | XR05CBY116N001010281251 | NHSA |
| 四川海梦智森生物制药有限公司 | 国药准字H20243785 | 0.1g | Category B (乙) | XR05CBY116N001010283150 | NHSA |
| 杭州云柏医药科技有限公司 | 国药准字H20234433 | 0.2克 | Category B (乙) | XR05CBY116N001010283549 | NHSA |
| 古戈尔药业(海南)有限责任公司 | 国药准字H20243084 | 0.1克 | Category B (乙) | XR05CBY116N001010284227 | NHSA |
| 浙江寰领医药科技有限公司 | 国药准字H20244740 | 0.2g | Category B (乙) | XR05CBY116N001010284239 | NHSA |
| 南京易亨制药有限公司 | 国药准字H20249427 | 0.1g | Category B (乙) | XR05CBY116N001010301605 | NHSA |
| 浙江众延医药科技有限公司 | 国药准字H20234160 | 0.1g | Category B (乙) | XR05CBY116N001010302753 | NHSA |
| 河北万龙药业有限公司 | 国药准字H20243804 | 0.1g | Category B (乙) | XR05CBY116N001010302766 | NHSA |
| 郑州韩都药业集团有限公司 | 国药准字H20255768 | 0.1g | Category B (乙) | XR05CBY116N001010303251 | NHSA |
| 浙江金华康恩贝生物制药有限公司 | 国药准字H20223846 | 0.2g | Category B (乙) | XR05CBY116N001010304656 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20223727 | 0.1g | Category B (乙) | XR05CBY116N001010304942 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 0.1g | Category B (乙) | XR05CBY116N001010305025 | NHSA |
| 桂林华信制药有限公司 | 国药准字H20223842 | 0.1g | Category B (乙) | XR05CBY116N001010305199 | NHSA |
| 海南赛立克药业有限公司 | 国药准字H20233011 | 0.2g | Category B (乙) | XR05CBY116N001010305805 | NHSA |
| 海南赞邦制药有限公司 | 国药准字H20000472 | 0.1g | Category B (乙) | XR05CBY116N001010305838 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20263738 | 0.2g | Category B (乙) | XR05CBY116N001010381251 | NHSA |
| 四川海梦智森生物制药有限公司 | 国药准字H20243785 | 0.1g | Category B (乙) | XR05CBY116N001010383150 | NHSA |
| 古戈尔药业(海南)有限责任公司 | 国药准字H20243084 | 0.1克 | Category B (乙) | XR05CBY116N001010384227 | NHSA |
| 浙江寰领医药科技有限公司 | 国药准字H20244740 | 0.2g | Category B (乙) | XR05CBY116N001010384239 | NHSA |
| 南京易亨制药有限公司 | 国药准字H20249427 | 0.1g | Category B (乙) | XR05CBY116N001010401605 | NHSA |
| 浙江众延医药科技有限公司 | 国药准字H20234160 | 0.1g | Category B (乙) | XR05CBY116N001010402753 | NHSA |
| 河北万龙药业有限公司 | 国药准字H20243804 | 0.1g | Category B (乙) | XR05CBY116N001010402766 | NHSA |
| 郑州韩都药业集团有限公司 | 国药准字H20255768 | 0.1g | Category B (乙) | XR05CBY116N001010403251 | NHSA |
| 浙江金华康恩贝生物制药有限公司 | 国药准字H20223846 | 0.2g | Category B (乙) | XR05CBY116N001010404656 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20223727 | 0.1g | Category B (乙) | XR05CBY116N001010404942 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 0.1g | Category B (乙) | XR05CBY116N001010405025 | NHSA |
| 桂林华信制药有限公司 | 国药准字H20223842 | 0.1g | Category B (乙) | XR05CBY116N001010405199 | NHSA |
| 海南赛立克药业有限公司 | 国药准字H20233011 | 0.2g | Category B (乙) | XR05CBY116N001010405805 | NHSA |
| 海南赞邦制药有限公司 | 国药准字H20000472 | 0.1g | Category B (乙) | XR05CBY116N001010405838 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20263738 | 0.2g | Category B (乙) | XR05CBY116N001010481251 | NHSA |
| 四川海梦智森生物制药有限公司 | 国药准字H20243785 | 0.1g | Category B (乙) | XR05CBY116N001010483150 | NHSA |
| 浙江寰领医药科技有限公司 | 国药准字H20244740 | 0.2g | Category B (乙) | XR05CBY116N001010484239 | NHSA |
| 广东百澳药业有限公司 | 国药准字H20030732 | 0.2g | Category B (乙) | XR05CBY116N001010500265 | NHSA |
| 浙江众延医药科技有限公司 | 国药准字H20234160 | 0.1g | Category B (乙) | XR05CBY116N001010502753 | NHSA |
| 河北万龙药业有限公司 | 国药准字H20243804 | 0.1g | Category B (乙) | XR05CBY116N001010502766 | NHSA |
| 浙江金华康恩贝生物制药有限公司 | 国药准字H20223846 | 0.2g | Category B (乙) | XR05CBY116N001010504656 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20223727 | 0.1g | Category B (乙) | XR05CBY116N001010504942 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 0.1g | Category B (乙) | XR05CBY116N001010505025 | NHSA |
| 桂林华信制药有限公司 | 国药准字H20223842 | 0.1g | Category B (乙) | XR05CBY116N001010505199 | NHSA |
| 海南赛立克药业有限公司 | 国药准字H20233011 | 0.2g | Category B (乙) | XR05CBY116N001010505805 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20263738 | 0.2g | Category B (乙) | XR05CBY116N001010581251 | NHSA |
| 四川海梦智森生物制药有限公司 | 国药准字H20243785 | 0.1g | Category B (乙) | XR05CBY116N001010583150 | NHSA |
| 浙江寰领医药科技有限公司 | 国药准字H20244740 | 0.2g | Category B (乙) | XR05CBY116N001010584239 | NHSA |
| 广东百澳药业有限公司 | 国药准字H20030732 | 0.2g | Category B (乙) | XR05CBY116N001010600265 | NHSA |
| 浙江众延医药科技有限公司 | 国药准字H20234160 | 0.1g | Category B (乙) | XR05CBY116N001010602753 | NHSA |
| 河北万龙药业有限公司 | 国药准字H20243804 | 0.1g | Category B (乙) | XR05CBY116N001010602766 | NHSA |
| 浙江金华康恩贝生物制药有限公司 | 国药准字H20223846 | 0.2g | Category B (乙) | XR05CBY116N001010604656 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20223727 | 0.1g | Category B (乙) | XR05CBY116N001010604942 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 0.1g | Category B (乙) | XR05CBY116N001010605025 | NHSA |
| 桂林华信制药有限公司 | 国药准字H20223842 | 0.1g | Category B (乙) | XR05CBY116N001010605199 | NHSA |
| 海南赛立克药业有限公司 | 国药准字H20233011 | 0.2g | Category B (乙) | XR05CBY116N001010605805 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20263738 | 0.2g | Category B (乙) | XR05CBY116N001010681251 | NHSA |
| 四川海梦智森生物制药有限公司 | 国药准字H20243785 | 0.1g | Category B (乙) | XR05CBY116N001010683150 | NHSA |
| 浙江寰领医药科技有限公司 | 国药准字H20244740 | 0.2g | Category B (乙) | XR05CBY116N001010684239 | NHSA |
| 广东百澳药业有限公司 | 国药准字H20030732 | 0.2g | Category B (乙) | XR05CBY116N001010700265 | NHSA |
| 浙江众延医药科技有限公司 | 国药准字H20234160 | 0.1g | Category B (乙) | XR05CBY116N001010702753 | NHSA |
| 河北万龙药业有限公司 | 国药准字H20243804 | 0.1g | Category B (乙) | XR05CBY116N001010702766 | NHSA |
| 浙江金华康恩贝生物制药有限公司 | 国药准字H20223846 | 0.2g | Category B (乙) | XR05CBY116N001010704656 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20223727 | 0.1g | Category B (乙) | XR05CBY116N001010704942 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 0.1g | Category B (乙) | XR05CBY116N001010705025 | NHSA |
| 桂林华信制药有限公司 | 国药准字H20223842 | 0.1g | Category B (乙) | XR05CBY116N001010705199 | NHSA |
| 海南赛立克药业有限公司 | 国药准字H20233011 | 0.2g | Category B (乙) | XR05CBY116N001010705805 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20263738 | 0.2g | Category B (乙) | XR05CBY116N001010781251 | NHSA |
| 四川海梦智森生物制药有限公司 | 国药准字H20243785 | 0.1g | Category B (乙) | XR05CBY116N001010783150 | NHSA |
| 浙江寰领医药科技有限公司 | 国药准字H20244740 | 0.2g | Category B (乙) | XR05CBY116N001010784239 | NHSA |
| 广东百澳药业有限公司 | 国药准字H20247160 | 0.1g | Category B (乙) | XR05CBY116N001010800265 | NHSA |
| 浙江众延医药科技有限公司 | 国药准字H20234160 | 0.1g | Category B (乙) | XR05CBY116N001010802753 | NHSA |
| 河北万龙药业有限公司 | 国药准字H20243804 | 0.1g | Category B (乙) | XR05CBY116N001010802766 | NHSA |
| 浙江金华康恩贝生物制药有限公司 | 国药准字H20223846 | 0.2g | Category B (乙) | XR05CBY116N001010804656 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20223727 | 0.1g | Category B (乙) | XR05CBY116N001010804942 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 0.1g | Category B (乙) | XR05CBY116N001010805025 | NHSA |
| 桂林华信制药有限公司 | 国药准字H20223842 | 0.1g | Category B (乙) | XR05CBY116N001010805199 | NHSA |
| 海南赛立克药业有限公司 | 国药准字H20233011 | 0.2g | Category B (乙) | XR05CBY116N001010805805 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20263738 | 0.2g | Category B (乙) | XR05CBY116N001010881251 | NHSA |
| 四川海梦智森生物制药有限公司 | 国药准字H20243785 | 0.1g | Category B (乙) | XR05CBY116N001010883150 | NHSA |
| 浙江寰领医药科技有限公司 | 国药准字H20244740 | 0.2g | Category B (乙) | XR05CBY116N001010884239 | NHSA |
| 广东百澳药业有限公司 | 国药准字H20247160 | 0.1g | Category B (乙) | XR05CBY116N001010900265 | NHSA |
| 浙江众延医药科技有限公司 | 国药准字H20234160 | 0.1g | Category B (乙) | XR05CBY116N001010902753 | NHSA |
| 河北万龙药业有限公司 | 国药准字H20243804 | 0.1g | Category B (乙) | XR05CBY116N001010902766 | NHSA |
| 浙江金华康恩贝生物制药有限公司 | 国药准字H20223846 | 0.2g | Category B (乙) | XR05CBY116N001010904656 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20223727 | 0.1g | Category B (乙) | XR05CBY116N001010904942 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 0.1g | Category B (乙) | XR05CBY116N001010905025 | NHSA |
| 桂林华信制药有限公司 | 国药准字H20223842 | 0.1g | Category B (乙) | XR05CBY116N001010905199 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20263738 | 0.2g | Category B (乙) | XR05CBY116N001010981251 | NHSA |
| 广东百澳药业有限公司 | 国药准字H20247160 | 0.1g | Category B (乙) | XR05CBY116N001011000265 | NHSA |
| 浙江众延医药科技有限公司 | 国药准字H20234160 | 0.1g | Category B (乙) | XR05CBY116N001011002753 | NHSA |
| 浙江金华康恩贝生物制药有限公司 | 国药准字H20223846 | 0.2g | Category B (乙) | XR05CBY116N001011004656 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20223727 | 0.1g | Category B (乙) | XR05CBY116N001011004942 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 0.1g | Category B (乙) | XR05CBY116N001011005025 | NHSA |
| 桂林华信制药有限公司 | 国药准字H20223842 | 0.1g | Category B (乙) | XR05CBY116N001011005199 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20263738 | 0.2g | Category B (乙) | XR05CBY116N001011081251 | NHSA |
| 广东百澳药业有限公司 | 国药准字H20247160 | 0.1g | Category B (乙) | XR05CBY116N001011100265 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20223727 | 0.1g | Category B (乙) | XR05CBY116N001011104942 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 0.1g | Category B (乙) | XR05CBY116N001011105025 | NHSA |
| 桂林华信制药有限公司 | 国药准字H20223842 | 0.1g | Category B (乙) | XR05CBY116N001011105199 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20223727 | 0.1g | Category B (乙) | XR05CBY116N001011204942 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 0.1g | Category B (乙) | XR05CBY116N001011205025 | NHSA |
| 桂林华信制药有限公司 | 国药准字H20223842 | 0.1g | Category B (乙) | XR05CBY116N001011205199 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20223727 | 0.1g | Category B (乙) | XR05CBY116N001011304942 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 0.1g | Category B (乙) | XR05CBY116N001011305025 | NHSA |
| 桂林华信制药有限公司 | 国药准字H20223842 | 0.1g | Category B (乙) | XR05CBY116N001011305199 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20223727 | 0.1g | Category B (乙) | XR05CBY116N001011404942 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 0.1g | Category B (乙) | XR05CBY116N001011405025 | NHSA |
| 桂林华信制药有限公司 | 国药准字H20223842 | 0.1g | Category B (乙) | XR05CBY116N001011405199 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20223727 | 0.1g | Category B (乙) | XR05CBY116N001011504942 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 0.1g | Category B (乙) | XR05CBY116N001011505025 | NHSA |
| 桂林华信制药有限公司 | 国药准字H20223842 | 0.1g | Category B (乙) | XR05CBY116N001011505199 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 0.1g | Category B (乙) | XR05CBY116N001011605025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 0.1g | Category B (乙) | XR05CBY116N001011705025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 0.1g | Category B (乙) | XR05CBY116N001011805025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 0.1g | Category B (乙) | XR05CBY116N001011905025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 0.1g | Category B (乙) | XR05CBY116N001012005025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 0.1g | Category B (乙) | XR05CBY116N001012105025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 0.1g | Category B (乙) | XR05CBY116N001012205025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 0.1g | Category B (乙) | XR05CBY116N001012305025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 0.1g | Category B (乙) | XR05CBY116N001012405025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 0.1g | Category B (乙) | XR05CBY116N001012505025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 0.1g | Category B (乙) | XR05CBY116N001012605025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 0.1g | Category B (乙) | XR05CBY116N001012705025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 0.1g | Category B (乙) | XR05CBY116N001012805025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 0.1g | Category B (乙) | XR05CBY116N001012905025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254217 | 0.1g | Category B (乙) | XR05CBY116N001013005025 | NHSA |
| 广东百澳药业有限公司 | 国药准字H20030732 | 0.2g | Category B (乙) | XR05CBY116N001020100265 | NHSA |
| 郑州韩都药业集团有限公司 | 国药准字H20255767 | 0.2g | Category B (乙) | XR05CBY116N001020103251 | NHSA |
| 哈尔滨华瑞生化药业有限责任公司 | 国药准字H20249277 | 0.2g | Category B (乙) | XR05CBY116N001020103634 | NHSA |
| 浙江金华康恩贝生物制药有限公司 | 国药准字H20247184 | 0.1g | Category B (乙) | XR05CBY116N001020104656 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 0.2g | Category B (乙) | XR05CBY116N001020105025 | NHSA |
| 海南赛立克药业有限公司 | 国药准字H20234324 | 0.1克 | Category B (乙) | XR05CBY116N001020105805 | NHSA |
| 海南赞邦制药有限公司 | 国药准字H20000471 | 0.2g | Category B (乙) | XR05CBY116N001020105838 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20263739 | 0.1g | Category B (乙) | XR05CBY116N001020181251 | NHSA |
| 四川海梦智森生物制药有限公司 | 国药准字H20243786 | 0.2g | Category B (乙) | XR05CBY116N001020183150 | NHSA |
| 杭州云柏医药科技有限公司 | 国药准字H20234434 | 0.1克 | Category B (乙) | XR05CBY116N001020183549 | NHSA |
| 古戈尔药业(海南)有限责任公司 | 国药准字H20243085 | 0.2克 | Category B (乙) | XR05CBY116N001020184227 | NHSA |
| 广东百澳药业有限公司 | 国药准字H20030732 | 0.2g | Category B (乙) | XR05CBY116N001020200265 | NHSA |
| 哈尔滨华瑞生化药业有限责任公司 | 国药准字H20249277 | 0.2g | Category B (乙) | XR05CBY116N001020203634 | NHSA |
| 浙江金华康恩贝生物制药有限公司 | 国药准字H20247184 | 0.1g | Category B (乙) | XR05CBY116N001020204656 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 0.2g | Category B (乙) | XR05CBY116N001020205025 | NHSA |
| 海南赛立克药业有限公司 | 国药准字H20234324 | 0.1克 | Category B (乙) | XR05CBY116N001020205805 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20263739 | 0.1g | Category B (乙) | XR05CBY116N001020281251 | NHSA |
| 四川海梦智森生物制药有限公司 | 国药准字H20243786 | 0.2g | Category B (乙) | XR05CBY116N001020283150 | NHSA |
| 杭州云柏医药科技有限公司 | 国药准字H20234434 | 0.1克 | Category B (乙) | XR05CBY116N001020283549 | NHSA |
| 古戈尔药业(海南)有限责任公司 | 国药准字H20243085 | 0.2克 | Category B (乙) | XR05CBY116N001020284227 | NHSA |
| 广东百澳药业有限公司 | 国药准字H20030732 | 0.2g | Category B (乙) | XR05CBY116N001020300265 | NHSA |
| 浙江金华康恩贝生物制药有限公司 | 国药准字H20247184 | 0.1g | Category B (乙) | XR05CBY116N001020304656 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 0.2g | Category B (乙) | XR05CBY116N001020305025 | NHSA |
| 海南赛立克药业有限公司 | 国药准字H20234324 | 0.1克 | Category B (乙) | XR05CBY116N001020305805 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20263739 | 0.1g | Category B (乙) | XR05CBY116N001020381251 | NHSA |
| 四川海梦智森生物制药有限公司 | 国药准字H20243786 | 0.2g | Category B (乙) | XR05CBY116N001020383150 | NHSA |
| 杭州云柏医药科技有限公司 | 国药准字H20234434 | 0.1克 | Category B (乙) | XR05CBY116N001020383549 | NHSA |
| 古戈尔药业(海南)有限责任公司 | 国药准字H20243085 | 0.2克 | Category B (乙) | XR05CBY116N001020384227 | NHSA |
| 广东百澳药业有限公司 | 国药准字H20030732 | 0.2g | Category B (乙) | XR05CBY116N001020400265 | NHSA |
| 浙江金华康恩贝生物制药有限公司 | 国药准字H20247184 | 0.1g | Category B (乙) | XR05CBY116N001020404656 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 0.2g | Category B (乙) | XR05CBY116N001020405025 | NHSA |
| 海南赛立克药业有限公司 | 国药准字H20234324 | 0.1克 | Category B (乙) | XR05CBY116N001020405805 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20263739 | 0.1g | Category B (乙) | XR05CBY116N001020481251 | NHSA |
| 四川海梦智森生物制药有限公司 | 国药准字H20243786 | 0.2g | Category B (乙) | XR05CBY116N001020483150 | NHSA |
| 广东百澳药业有限公司 | 国药准字H20030732 | 0.2g | Category B (乙) | XR05CBY116N001020500265 | NHSA |
| 浙江金华康恩贝生物制药有限公司 | 国药准字H20247184 | 0.1g | Category B (乙) | XR05CBY116N001020504656 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 0.2g | Category B (乙) | XR05CBY116N001020505025 | NHSA |
| 海南赛立克药业有限公司 | 国药准字H20234324 | 0.1克 | Category B (乙) | XR05CBY116N001020505805 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20263739 | 0.1g | Category B (乙) | XR05CBY116N001020581251 | NHSA |
| 四川海梦智森生物制药有限公司 | 国药准字H20243786 | 0.2g | Category B (乙) | XR05CBY116N001020583150 | NHSA |
| 广东百澳药业有限公司 | 国药准字H20030732 | 0.2g | Category B (乙) | XR05CBY116N001020600265 | NHSA |
| 浙江金华康恩贝生物制药有限公司 | 国药准字H20247184 | 0.1g | Category B (乙) | XR05CBY116N001020604656 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 0.2g | Category B (乙) | XR05CBY116N001020605025 | NHSA |
| 海南赛立克药业有限公司 | 国药准字H20234324 | 0.1克 | Category B (乙) | XR05CBY116N001020605805 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20263739 | 0.1g | Category B (乙) | XR05CBY116N001020681251 | NHSA |
| 四川海梦智森生物制药有限公司 | 国药准字H20243786 | 0.2g | Category B (乙) | XR05CBY116N001020683150 | NHSA |
| 广东百澳药业有限公司 | 国药准字H20030732 | 0.2g | Category B (乙) | XR05CBY116N001020700265 | NHSA |
| 浙江金华康恩贝生物制药有限公司 | 国药准字H20247184 | 0.1g | Category B (乙) | XR05CBY116N001020704656 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 0.2g | Category B (乙) | XR05CBY116N001020705025 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20263739 | 0.1g | Category B (乙) | XR05CBY116N001020781251 | NHSA |
| 四川海梦智森生物制药有限公司 | 国药准字H20243786 | 0.2g | Category B (乙) | XR05CBY116N001020783150 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 0.2g | Category B (乙) | XR05CBY116N001020805025 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20263739 | 0.1g | Category B (乙) | XR05CBY116N001020881251 | NHSA |
| 四川海梦智森生物制药有限公司 | 国药准字H20243786 | 0.2g | Category B (乙) | XR05CBY116N001020883150 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 0.2g | Category B (乙) | XR05CBY116N001020905025 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20263739 | 0.1g | Category B (乙) | XR05CBY116N001020981251 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 0.2g | Category B (乙) | XR05CBY116N001021005025 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20263739 | 0.1g | Category B (乙) | XR05CBY116N001021081251 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 0.2g | Category B (乙) | XR05CBY116N001021105025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 0.2g | Category B (乙) | XR05CBY116N001021205025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 0.2g | Category B (乙) | XR05CBY116N001021305025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 0.2g | Category B (乙) | XR05CBY116N001021405025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 0.2g | Category B (乙) | XR05CBY116N001021505025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 0.2g | Category B (乙) | XR05CBY116N001021605025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 0.2g | Category B (乙) | XR05CBY116N001021705025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 0.2g | Category B (乙) | XR05CBY116N001021805025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 0.2g | Category B (乙) | XR05CBY116N001021905025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 0.2g | Category B (乙) | XR05CBY116N001022005025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 0.2g | Category B (乙) | XR05CBY116N001022105025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 0.2g | Category B (乙) | XR05CBY116N001022205025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 0.2g | Category B (乙) | XR05CBY116N001022305025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 0.2g | Category B (乙) | XR05CBY116N001022405025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 0.2g | Category B (乙) | XR05CBY116N001022505025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 0.2g | Category B (乙) | XR05CBY116N001022605025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 0.2g | Category B (乙) | XR05CBY116N001022705025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 0.2g | Category B (乙) | XR05CBY116N001022805025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 0.2g | Category B (乙) | XR05CBY116N001022905025 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20254218 | 0.2g | Category B (乙) | XR05CBY116N001023005025 | NHSA |
| 广东百澳药业有限公司 | 国药准字H20247160 | 0.1g | Category B (乙) | XR05CBY116N001030100265 | NHSA |
| 浙江众延医药科技有限公司 | 国药准字H20269242 | 0.2g | Category B (乙) | XR05CBY116N001010184225 | NHSA |
| 浙江众延医药科技有限公司 | 国药准字H20269242 | 0.2g | Category B (乙) | XR05CBY116N001010284225 | NHSA |
| 浙江众延医药科技有限公司 | 国药准字H20269242 | 0.2g | Category B (乙) | XR05CBY116N001010384225 | NHSA |
| 浙江众延医药科技有限公司 | 国药准字H20269242 | 0.2g | Category B (乙) | XR05CBY116N001010484225 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 4 filings and 4 distinct first applicants.
Generic 3 · Supplement 1
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 江西仁齐制药有限公司 | CYHS2601886 | Generic | 2026/08/04 | Not stated by source | CDE |
| 重庆科瑞制药（集团）有限公司 | CYHS2600840 | Generic | 2026/04/11 | Not stated by source | CDE |
| 浙江众延医药科技有限公司;石家庄市华新药业有限责任公司 | CYHB2600413 | Supplement | 2026/02/28 | Not stated by source | CDE |
| 武汉远大弘元股份有限公司;湖北省八峰药化股份有限公司 | CYHS2502924 | Generic | 2025/08/12 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 2 filings and 2 distinct first applicants.
API registrations
Non-component matches: 12 companies with A status and 5 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 乙酰半胱氨酸 | 浙江海昌药业股份有限公司 | Y20260000718 | I | Exact ingredient | 2026/08/14 | CDE |
| 乙酰半胱氨酸 | PharmaZell GmbH | Y20250001320 | I | Exact ingredient | 2026/04/28 | CDE |
| 乙酰半胱氨酸 | 浙江海洲制药股份有限公司 | Y20260000217 | I | Exact ingredient | 2026/03/27 | CDE |
| 乙酰半胱氨酸 | 津药药业股份有限公司 | Y20240001520 | I | Exact ingredient | 2025/05/28 | CDE |
| 乙酰半胱氨酸 | 湖南九典宏阳制药有限公司 | Y20240001419 | A | Exact ingredient | 2026/09/10 | CDE |
| 乙酰半胱氨酸 | 浙江金华康恩贝生物制药有限公司 | Y20240001287 | A | Exact ingredient | 2026/06/02 | CDE |
| 乙酰半胱氨酸 | 湖南华纳大药厂手性药物有限公司 | Y20230001045 | A | Exact ingredient | 2025/05/20 | CDE |
| 乙酰半胱氨酸 | 浙江诚意药业股份有限公司 | Y20220000261 | A | Exact ingredient | 2024/05/22 | CDE |
| 乙酰半胱氨酸 | 七星化学制药股份有限公司 | Y20220000066 | A | Exact ingredient | 2024/01/25 | CDE |
| 乙酰半胱氨酸 | 山西阳和药业有限公司 | Y20210001235 | A | Exact ingredient | 2025/02/06 | CDE |
| 乙酰半胱氨酸 | 福建南方制药股份有限公司 | Y20210001183 | A | Exact ingredient | 2024/09/17 | CDE |
| 乙酰半胱氨酸 | 浙江赛默制药有限公司 | Y20210001203 | A | Exact ingredient | 2025/10/18 | CDE |
| 乙酰半胱氨酸 | Nippon Rika Co., Ltd. | Y20200000078 | A | Exact ingredient | 2023/03/24 | CDE |
| 乙酰半胱氨酸 | 武汉远大弘元股份有限公司 | Y20190009549 | A | Exact ingredient | 2025/09/24 | CDE |
| 乙酰半胱氨酸 | F.I.S. Fabbrica Italiana Sintetici S.P.A. | Y20190009052 | A | Exact ingredient | 2024/05/22 | CDE |
| 乙酰半胱氨酸 | 浙江诚意药业股份有限公司 | Y20190007528 | A | Exact ingredient | 2024/05/22 | CDE |
| 乙酰半胱氨酸 | 湖北新生源生物工程有限公司 | Y20190006101 | A | Exact ingredient | 2026/01/29 | CDE |
| 乙酰半胱氨酸 | MOEHS IBERICA S.L. | Y20170000715 | I | Exact ingredient | — | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
- No matching records were found in the currently loaded source data; coverage dates are listed below.
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Acetylcysteine Granules
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy